Completed PHASE2 INTERVENTIONAL 5-arm NCT01516151

Assess the Safety and Efficacy of NKPL66 (CaPre™) in the Treatment of Mild-to-high Hypertriglyceridemia

A Randomized Open-label Dose-ranging, Multi-center Trial to Assess the Safety and Efficacy of NKPL66(CaPre™) in the Treatment of Mild-to-high Hypertriglyceridemia

Sponsor: Grace Therapeutics Inc.

Conditions Hypertriglyceridemia

Interventions CaPre™ Lipid Lowering Medication

Updated 7 times since 2017 Last updated: Jan 7, 2014 Started: Dec 31, 2011 Primary completion: May 31, 2013 Completion: Sep 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01516151, this PHASE2 trial focuses on Hypertriglyceridemia and remains completed. Sponsored by Grace Therapeutics Inc., it has been updated 7 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Feb 2025 — Sep 2025 [monthly]

Completed PHASE2
Sep 2024 — Feb 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Dec 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Grace Therapeutics Inc.
JSS Medical Research Inc.

Data source: Grace Therapeutics Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abbotsford, Canada , Aurora, Canada , Brampton, Canada , Cambridge, Canada , Chatam, Canada , Colingwood, Canada , Courcelette, Canada , Delson, Canada , Dieppe, Canada , Dolbeau-Mistassini, Canada and 24 more locations